Acadia Pharmaceuticals (ACAD) Free Cash Flow (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Free Cash Flow of $28.8 million for Q1 2026, up 41.56% year-over-year from $20.3 million in Q1 2025, and up 154.55% quarter-over-quarter from -$52.7 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Free Cash Flow (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Free Cash Flow history runs 17 years deep, the most recent figure standing at $28.8 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 41.56% year-over-year to $28.8 million; the TTM figure through Mar 2026 stood at $113.6 million (down 23.48% YoY), while the FY2025 annual figure was $105.1 million, down 33.11% from the prior year.
- Free Cash Flow for Q1 2026 stood at $28.8 million, up from -$52.7 million in the prior quarter.
- The five-year high for Free Cash Flow was $85.4 million in Q4 2023, with the low at -$76.3 million in Q1 2022.
- The 5-year median for Free Cash Flow is $20.3 million (2025), against an average of $11.4 million.
- Peak annual rise in Free Cash Flow reached 457.97% in 2023, while the deepest fall reached 8009.35% in 2023.
- Acadia Pharmaceuticals' Free Cash Flow stood at -$23.9 million in 2022, then surged by 457.97% to $85.4 million in 2023, then slumped by 53.24% to $39.9 million in 2024, then slumped by 232.08% to -$52.7 million in 2025, then soared by 154.55% to $28.8 million in 2026.
- Business Quant data shows ACAD's Free Cash Flow at $28.8 million in Q1 2026, -$52.7 million in Q4 2025, and $73.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 95.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 95.69 Mn |
| Jun 30, 2026 | 95.69 Mn |
| Mar 31, 2026 | 28.77 Mn |
| Mar 31, 2026 | 28.77 Mn |
| Dec 31, 2025 | -52.74 Mn |
| Dec 31, 2025 | -52.74 Mn |
| Sep 30, 2025 | 73.90 Mn |
| Sep 30, 2025 | 73.90 Mn |
| Jun 30, 2025 | 63.66 Mn |
| Jun 30, 2025 | 63.66 Mn |
| Mar 31, 2025 | 20.32 Mn |
| Mar 31, 2025 | 20.32 Mn |
| Dec 31, 2024 | 39.93 Mn |
| Dec 31, 2024 | 39.93 Mn |
| Sep 30, 2024 | 63.18 Mn |
| Sep 30, 2024 | 63.18 Mn |
| Jun 30, 2024 | 25.01 Mn |
| Jun 30, 2024 | 25.01 Mn |
| Mar 31, 2024 | 29.08 Mn |
| Mar 31, 2024 | 29.08 Mn |